A critical review of the mechanism of action for the selective serotonin reuptake inhibitors: Do these drugs possess anti-inflammatory properties and how relevant is this in the treatment of depression?

Neuropharmacology

Volumn 67, Issue , 2013, Pages 304-317

  Walker, Frederick Rohan ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Anti inflammatory; Antidepressants; Cytokines; Depression; Inflammation; Inflammatory; Monoamine; Monoamine theory; Neuroinflammation; Neuroinflammatory; Pro inflammatory; Reuptake inhibitor; SSRI

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; BETA ADRENERGIC RECEPTOR; C REACTIVE PROTEIN; CELECOXIB; CLOMIPRAMINE; CYCLIC AMP; FLUOXETINE; IMIPRAMINE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MINOCYCLINE; MOCLOBEMIDE; MORPHINE; NEUROTROPHIN; OMEGA 3 FATTY ACID; PAROXETINE; PLACEBO; REBOXETINE; SEROTONIN 1A RECEPTOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN TRANSPORTER; TRICYCLIC ANTIDEPRESSANT AGENT; TUMOR NECROSIS FACTOR ALPHA; VENLAFAXINE;

ANTIINFLAMMATORY ACTIVITY; BINDING AFFINITY; BIPOLAR DEPRESSION; BLURRED VISION; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; CONSTIPATION; CYTOKINE RELEASE; DEGENERATIVE DISEASE; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MEMORY DISORDER; MONOTHERAPY; NAUSEA; NEGATIVE FEEDBACK; NERVOUS SYSTEM INFLAMMATION; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECEPTOR DOWN REGULATION; REVIEW; SEROTONINERGIC SYSTEM; SEXUAL DYSFUNCTION; SIGNAL TRANSDUCTION; SUICIDE ATTEMPT; TREATMENT DURATION; TREMOR; UPREGULATION; URINE RETENTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; HUMANS; INFLAMMATION; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84873391360     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2012.10.002     Document Type: Review

References (220)

1. A. Adell, and F. Artigas Differential effects of clomipramine given locally or systemically on extracellular 5-hydroxytryptamine in raphe nuclei and frontal cortex. An in vivo brain microdialysis study Naunyn Schmiedebergs Arch. Pharmacol. 343 3 1991 237 244
2. G.K. Aghajanian, and Y.Y. Wang Common alpha 2- and opiate effector mechanisms in the locus coeruleus: intracellular studies in brain slices Neuropharmacology 26 7B 1987 793 799
3. C. Anacker, P.A. Zunszain, A. Cattaneo, and L.A. Carvalho Antidepressants increase human hippocampal neurogenesis by activating the glucocorticoid receptor Mol. Psychiatry 16 7 2011 738 750
4. I.M. Anderson SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability Depress. Anxiety 7 Suppl. 1 1998 11 17
5. I.M. Anderson Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability J. Affect Disord. 58 1 2000 19 36
6. J.M. Andrews, and C.B. Nemeroff Contemporary management of depression Am. J. Med. 97 6A 1994 24S 32S
7. G.W. Ashcroft, D. Eccleston, L.G. Murray, and A.I.M. Glen Modified amine hypothesis for the aetiology of affective illness Lancet 2 7777 1972 573 577
8. S.B. Auerbach, J.F. Lundberg, and S. Hjorth Differential inhibition of serotonin release by 5-HT and NA reuptake blockers after systemic administration Neuropharmacology 34 1 1995 89 96
9. A. Barbon, L. Caracciolo, C. Orlandi, and L. Musazzi Chronic antidepressant treatments induce a time-dependent up-regulation of AMPA receptor subunit protein levels Neurochem. Int. 59 6 2011 896 905
10. P. Bartholoma, N. Erlandsson, K. Kaufmann, and O.G. Rossler Neuronal cell death induced by antidepressants: lack of correlation with Egr-1, NF-kappa B and extracellular signal-regulated protein kinase activation Biochem. Pharmacol. 63 8 2002 1507 1516
11. C.L. Barton, and P.H. Hutson Inhibition of hippocampal 5-HT synthesis by fluoxetine and paroxetine: evidence for the involvement of both 5-HT1A and 5-HT1B/D autoreceptors Synapse 31 1 1999 13 19
12. B.T. Baune, U. Dannlowski, K. Domschke, and D.G. Janssen The interleukin 1 beta (IL1B) gene is associated with failure to achieve remission and impaired emotion processing in major depression Biol. Psychiatry 67 6 2010 543 549
13. P. Bech Is the antidepressive effect of second-generation antidepressants a myth? Psychol. Med. 40 2 2010 181 186
14. A.M. Bielecka, M. Paul-Samojedny, and E. Obuchowicz Moclobemide exerts anti-inflammatory effect in lipopolysaccharide-activated primary mixed glial cell culture Naunyn Schmiedebergs Arch. Pharmacol. 382 5-6 2010 409 417
15. M.H. Bloch, and J. Hannestad Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis Mol. Psychiatry 2011 Sep 20 10.1038/mp
16. F.J. Bosker, A. Klompmakers, and H.G. Westenberg Postsynaptic 5-HT1A receptors mediate 5-hydroxytryptamine release in the amygdala through a feedback to the caudal linear raphe Eur. J. Pharmacol. 333 2-3 1997 147 157
17. L.S. Branco-de-Almeida, M. Kajiya, C.R. Cardoso, and M.J. Silva Selective serotonin reuptake inhibitors attenuate the antigen presentation from dendritic cells to effector T lymphocytes FEMS Immunol. Med. Microbiol. 62 3 2011 283 294
18. K. Broich Committee for Medicinal Products for Human Use (CHMP) assessment on efficacy of antidepressants Eur. Neuropsychopharmacol. 19 5 2009 305 308
19. N. Brunello, S. Alboni, G. Capone, and C. Benatti Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression Int. Clin. Psychopharmacol. 21 4 2006 219 225
20. S. Campbell, and G. MacQueen An update on regional brain volume differences associated with mood disorders Curr. Opin. Psychiatry 19 1 2006 25 33
21. M. Catena-Dell'Osso, C. Bellantuono, G. Consoli, and S. Baroni Inflammatory and neurodegenerative pathways in depression: a new avenue for antidepressant development? Curr. Med. Chem. 18 2 2011 245 255
22. A. Ceci, A. Baschirotto, and F. Borsini The inhibitory effect of 8-OH-DPAT on the firing activity of dorsal raphe serotoninergic neurons in rats is attenuated by lesion of the frontal cortex Neuropharmacology 33 5 1994 709 713
23. A.P. Cerri, B. Arosio, C. Viazzoli, and R. Confalonieri 308(G/A) TNF-alpha gene polymorphism and risk of depression late in the life Arch. Gerontol. Geriatr. 49 Suppl. 1 2009 29 34
24. A.P. Cerri, B. Arosio, C. Viazzoli, and R. Confalonieri The -308 (G/A) single nucleotide polymorphism in the TNF-alpha gene and the risk of major depression in the elderly Int. J. Geriatr. Psychiatry 25 3 2010 219 223
25. M. Clerici, B. Arosio, E. Mundo, and E. Cattaneo Cytokine polymorphisms in the pathophysiology of mood disorders CNS Spectr. 14 8 2009 419 425
26. D. Cotter, D. Mackay, G. Chana, and C. Beasley Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder Cereb. Cortex 12 4 2002 386 394
27. D. Cotter, D. Mackay, S. Landau, and R. Kerwin Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder Arch. Gen. Psychiatry 58 6 2001 545 553
28. B. Czéh, and B. Di Benedetto Antidepressants act directly on astrocytes: evidences and functional consequences Eur. Neuropsychopharmacol. 2012 May 18 [Epub ahead of print]
29. M. Dam, P. Tonin, A. De Boni, and G. Pizzolato Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy Stroke 27 7 1996 1211 1214
30. C. Dello Russo, A.I. Boullerne, V. Gavrilyuk, and D.L. Feinstein Inhibition of microglial inflammatory responses by norepinephrine: effects on nitric oxide and interleukin-1beta production J. Neuroinflammation 1 1 2004 9
31. M. Diamond, J.P. Kelly, and T.J. Connor Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade Eur. Neuropsychopharmacol. 16 7 2006 481 490
32. Y. Dowlati, N. Herrmann, W. Swardfager, and H. Liu A meta-analysis of cytokines in major depression Biol. Psychiatry 67 5 2010 446 457
33. R.S. Duman Novel therapeutic approaches beyond the serotonin receptor Biol. Psychiatry 44 5 1998 324 335
34. R.S. Duman, G.R. Heninger, and E.J. Nestler A molecular and cellular theory of depression Arch. Gen. Psychiatry 54 7 1997 597 606
35. I. Elkin Depression severity and effect of antidepressant medications JAMA 303 16 2010 1596 author reply 1599
36. P. Ellis Australian and New Zealand clinical practice guidelines for the treatment of depression Aust. N. Z. J. Psychiatry 38 6 2004 389 407
37. H. Eyre, and B.T. Baune Neuroplastic changes in depression: a role for the immune system Psychoneuroendocrinology 37 9 2012 Sep 1397 1416
38. G.A. Fava, and E. Offidani The mechanisms of tolerance in antidepressant action Prog. Neuropsychopharmacol. Biol. Psychiatry 35 7 2011 1593 1602
39. M. Fava Partial responders to antidepressant treatment: switching strategies J. Clin. Psychiatry 70 7 2009 e24
40. M. Fava, and K.G. Davidson Definition and epidemiology of treatment-resistant depression Psychiatr. Clin. North. Am. 19 2 1996 179 200
41. T.M. Felton, T.B. Kang, S. Hjorth, and S.B. Auerbach Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex Naunyn Schmiedebergs Arch. Pharmacol. 367 3 2003 297 305
42. D. Fergusson, S. Doucette, K.C. Glass, and S. Shapiro Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials BMJ 330 7488 2005 396
43. K.N. Fountoulakis, and H.J. Moller Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data Int. J. Neuropsychopharmacol. 14 3 2011 405 412
44. K.N. Fountoulakis, and H.J. Möller Antidepressant drugs and the response in the placebo group: the real problem lies in our understanding of the issue J. Psychopharmacol. 26 5 2012 May 744 750
45. J.C. Fournier, R.J. DeRubeis, S.D. Hollon, and S. Dimidjian Antidepressant drug effects and depression severity: a patient-level meta-analysis JAMA 303 1 2010 47 53
46. P. Galecki, A. Florkowski, M. Bienkiewicz, and J. Szemraj Functional polymorphism of cyclooxygenase-2 gene (G-765C) in depressive patients Neuropsychobiology 62 2 2010 116 120
47. R.D. Gibbons, C.H. Brown, K. Hur, and S.M. Marcus Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents Am. J. Psychiatry 164 9 2007 1356 1363
48. A.H. Glassman Depression severity and effect of antidepressant medications JAMA 303 16 2010 1598 author reply 1599
49. A.H. Glassman, C.M. O'Connor, R.M. Califf, and K. Swedberg Sertraline treatment of major depression in patients with acute MI or unstable angina JAMA 288 6 2002 701 709
50. P. Gotzsche Depression severity and effect of antidepressant medications JAMA 303 16 2010 1597 author reply 1599
51. P.E. Greenberg, and H.G. Birnbaum The economic burden of depression in the US: societal and patient perspectives Expert Opin. Pharmacother. 6 3 2005 369 376
52. P.E. Greenberg, R.C. Kessler, H.G. Birnbaum, and S.A. Leong The economic burden of depression in the United States: how did it change between 1990 and 2000? J. Clin. Psychiatry 64 12 2003 1465 1475
53. G.J. Guillemin, G. Smythe, O. Takikawa, and B.J. Brew Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons Glia 49 1 2005 15 23
54. G.J. Guillemin, L. Wang, and B.J. Brew Quinolinic acid selectively induces apoptosis of human astrocytes: potential role in AIDS dementia complex J. Neuroinflammation 2 2005 16
55. D. Gunnell, J. Saperia, and D. Ashby Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review BMJ 330 7488 2005 385
56. E. Ha, K.H. Jung, B.K. Choe, and J.H. Bae Fluoxetine increases the nitric oxide production via nuclear factor kappa B-mediated pathway in BV2 murine microglial cells Neurosci. Lett. 397 3 2006 185 189
57. M. Hajos, E. Hajos-Korcsok, and T. Sharp Role of the medial prefrontal cortex in 5-HT1A receptor-induced inhibition of 5-HT neuronal activity in the rat Br. J. Pharmacol. 126 8 1999 1741 1750
58. J. Hannestad, N. Dellagioia, and M. Bloch The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis Neuropsychopharmacology 36 12 2011 Nov 2452
59. R.A. Hansen, G. Gartlehner, K.N. Lohr, and B.N. Gaynes Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder Ann. Intern. Med. 143 6 2005 415 426
60. B.L. Hart Behavior of sick animals Vet. Clin. North. Am. Food Anim. Pract. 3 2 1987 383 391
61. B.H. Harvey Is major depressive disorder a metabolic encephalopathy? Hum. Psychopharmacol. 23 5 2008 371 384
62. S. Hashioka, A. Klegeris, A. Monji, and T. Kato Antidepressants inhibit interferon-gamma-induced microglial production of IL-6 and nitric oxide Exp. Neurol. 206 1 2007 33 42
63. S. Hashioka, P.L. McGeer, A. Monji, and S. Kanba Anti-inflammatory effects of antidepressants: possibilities for preventives against Alzheimer's disease Cent. Nerv. Syst. Agents Med. Chem. 9 1 2009 12 19
64. D. Healy The Antidepressant Era 1999 Harvard University Press Cambridge
65. M.E. Henry, M.E. Schmidt, J. Hennen, and R.A. Villafuerte A comparison of brain and serum pharmacokinetics of R-fluoxetine and racemic fluoxetine: a 19-F MRS study Neuropsychopharmacology 30 8 2005 1576 1583
66. P. Hicks, and X.P. Hicks Depression severity and effect of antidepressant medications JAMA 303 16 2010 1598 author reply 1599
67. C. Hiemke, and S. Hartter Pharmacokinetics of selective serotonin reuptake inhibitors Pharmacol. Ther. 85 1 2000 11 28
68. I. Hindmarch Expanding the horizons of depression: beyond the monoamine hypothesis Hum. Psychopharmacol. 16 3 2001 203 218
69. I. Hindmarch Beyond the monoamine hypothesis: mechanisms, molecules and methods Eur. Psychiatry 17 Suppl. 3 2002 294 299
70. M. Hinwood, J. Morandini, T.A. Day, and F.R. Walker Evidence that microglia mediate the neurobiological effects of chronic psychological stress on the medial prefrontal cortex Cereb. Cortex 22 6 2012 1442 1454
71. M. Hinwood, R.J. Tynan, J.L. Charnley, S.B. Beynon, T.A. Day, and F.R. Walker Chronic stress induced remodeling of the prefrontal cortex: structural re-organization of microglia and the inhibitory effect of minocycline Cereb. Cortex 2012 Jun 17
72. S. Hjorth, and S.B. Auerbach Further evidence for the importance of 5-HT1A autoreceptors in the action of selective serotonin reuptake inhibitors Eur. J. Pharmacol. 260 2-3 1994 251 255
73. C.J. Hong, Y.W. Yu, T.J. Chen, and S.J. Tsai Interleukin-6 genetic polymorphism and Chinese major depression Neuropsychobiology 52 4 2005 202 205
74. J. Horder, P. Matthews, and R. Waldmann Placebo, Prozac and PLoS: significant lessons for psychopharmacology J. Psychopharmacol. 25 10 2011 Oct 1277 1288
75. H. Horikawa, T.A. Kato, Y. Mizoguchi, and A. Monji Inhibitory effects of SSRIs on IFN-gamma induced microglial activation through the regulation of intracellular calcium Prog. Neuropsychopharmacol. Biol. Psychiatry 34 7 2010 1306 1316
76. M. Hotopf, G. Lewis, and C. Normand Are SSRIs a cost-effective alternative to tricyclics? Br. J. Psychiatry 168 4 1996 404 409
77. M.B. Howren, D.M. Lamkin, and J. Suls Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis Psychosom Med. 71 2 2009 171 186
78. T.W. Hu The economic burden of depression and reimbursement policy in the Asia Pacific region Australas Psychiatry 12 Suppl. 2004 S11 S15
79. J. Hwang, L.T. Zheng, J. Ock, and M.G. Lee Inhibition of glial inflammatory activation and neurotoxicity by tricyclic antidepressants Neuropharmacology 55 5 2008 826 834
80. J.P. Hwang, S.J. Tsai, C.J. Hong, and C.H. Yang Interleukin-1 beta -511C/T genetic polymorphism is associated with age of onset of geriatric depression Neuromolecular Med. 11 4 2009 322 327
81. J. Hyttel Comparative pharmacology of selective serotonin re-uptake inhibitors (SSRIs) Nordic J. Psychiatry 47 Suppl. 30 1993 5 12
82. G.K. Isbister, S.J. Bowe, A. Dawson, and I.M. Whyte Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose J. Toxicol. Clin. Toxicol. 42 3 2004 277 285
83. D.G. Janssen, R.N. Caniato, J.C. Verster, and B.T. Baune A psychoneuroimmunological review on cytokines involved in antidepressant treatment response Hum. Psychopharmacol. 25 3 2010 201 215
84. C.S. John, K.L. Smith, A. Van't Veer, H.S. Gompf, W.A. Carlezon Jr., B.M. Cohen, D. Ongr, and A.J. Bechtholt-Gompf Blockade of astrocytic glutamate uptake in the prefrontal cortex induces anhedonia Neuropsychopharmacology 37 11 2012 Oct 2467 2475 10.1038/npp.2012.105
85. R.E. Jorge, L. Acion, D. Moser, and H.P. Adams Jr. Escitalopram and enhancement of cognitive recovery following stroke Arch. Gen. Psychiatry 67 2 2010 187 196
86. R.E. Jorge, R.G. Robinson, S. Arndt, and S. Starkstein Mortality and poststroke depression: a placebo-controlled trial of antidepressants Am. J. Psychiatry 160 10 2003 1823 1829
87. T. Kato, A. Monji, S. Hashioka, and S. Kanba Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro Schizophr Res. 92 1-3 2007 108 115
88. M.J. Keiser, V. Setola, J.J. Irwin, and C. Laggner Predicting new molecular targets for known drugs Nature 462 7270 2009 175 181
89. S. Kent, R.M. Bluthe, R. Dantzer, and A.J. Hardwick Different receptor mechanisms mediate the pyrogenic and behavioral effects of interleukin 1 Proc. Natl. Acad. Sci. U. S. A. 89 19 1992 9117 9120
90. A. Khan, S. Khan, R. Kolts, and W.A. Brown Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports Am. J. Psychiatry 160 4 2003 790 792
91. I. Kirsch, B.J. Deacon, T.B. Huedo-Medina, and A. Scoboria Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration PLoS Med. 5 2 2008 e45
92. J.W. Koo, S.J. Russo, D. Ferguson, and E.J. Nestler Nuclear factor-kappaB is a critical mediator of stress-impaired neurogenesis and depressive behavior Proc. Natl. Acad. Sci. U. S. A. 107 6 2010 2669 2674
93. P.C. Koolschijn, N.E. van Haren, G.J. Lensvelt-Mulders, and H.E. Hulshoff Pol Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies Hum. Brain Mapp. 30 11 2009 3719 3735
94. M. Kubera, G. Kenis, E. Bosmans, and M. Kajta Stimulatory effect of antidepressants on the production of IL-6 Int. Immunopharmacol. 4 2 2004 185 192
95. M. Kubera, E. Obuchowicz, L. Goehler, J. Brzeszcz, and M. Maes In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression Prog. Neuropsychopharmacol. Biol. Psychiatry 35 3 2011 Apr 29 744 759
96. A. Kugaya, and G. Sanacora Beyond monoamines: glutamatergic function in mood disorders CNS Spectr. 10 10 2005 808 819
97. J.R. Lacasse, and J. Leo Serotonin and depression: a disconnect between the advertisements and the scientific literature PLoS Med. 2 12 2005 e392
98. F. Lamers, P. de Jonge, W.A. Nolen, and J.H. Smit Identifying depressive subtypes in a large cohort study: results from the Netherlands Study of Depression and Anxiety (NESDA) J. Clin. Psychiatry 71 12 2010 1582 1589
99. R. Lane, and D. Baldwin Selective serotonin reuptake inhibitor-induced serotonin syndrome: review J. Clin. Psychopharmacol. 17 3 1997 208 221
100. A. Laugeray, J.M. Launay, J. Callebert, and A. Surget Peripheral and cerebral metabolic abnormalities of the tryptophan-kynurenine pathway in a murine model of major depression Behav. Brain Res. 210 1 2010 84 91
101. J.S. Lee, I.D. Jung, C.M. Lee, and K.T. Noh Venlafaxine inhibits the development and differentiation of dendritic cells through the regulation of P-glycoprotein Int. Immunopharmacol. 11 9 2011 1348 1357
102. B.E. Leonard Current status of the biogenic amine theory of depression Neurochem. Int. 4 5 1982 339 350
103. N. Li, R.J. Liu, J.M. Dwyer, and M. Banasr Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure Biol. Psychiatry 69 8 2011 754 761
104. C.M. Lim, S.W. Kim, J.Y. Park, and C. Kim Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect J. Neurosci. Res. 87 4 2009 1037 1045
105. D. Lim, K. Sanderson, and G. Andrews Lost productivity among full-time workers with mental disorders J. Ment. Health Policy Econ. 3 3 2000 139 146
106. P.Y. Lin, and K.P. Su A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids J. Clin. Psychiatry 68 7 2007 1056 1061
107. C. Liston, M.M. Miller, D.S. Goldwater, and J.J. Radley Stress-induced alterations in prefrontal cortical dendritic morphology predict selective impairments in perceptual attentional set-shifting J. Neurosci. 26 30 2006 7870 7874
108. Y. Liu, R.C. Ho, and A. Mak Interleukin (IL)-6, tumour necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression J. Affect Disord. 139 3 2012 Aug 230 239
109. S. Mace, and D. Taylor Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression Expert Opin. Pharmacother. 1 5 2000 917 933
110. R. Machado-Vieira, P. Yuan, N. Brutsche, and N. DiazGranados Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist J. Clin. Psychiatry 70 12 2009 1662 1666
111. F.R. Mackay, N.R. Dunn, R.M. Martin, and G.L. Pearce Newer antidepressants: a comparison of tolerability in general practice Br. J. Gen. Pract. 49 448 1999 892 896
112. M. Maes A review on the acute phase response in major depression Rev. Neurosci. 4 4 1993 407 416
113. M. Maes Evidence for an immune response in major depression: a review and hypothesis Prog. Neuropsychopharmacol. Biol. Psychiatry 19 1 1995 11 38
114. M. Maes, G. Kenis, M. Kubera, and M. De Baets The negative immunoregulatory effects of fluoxetine in relation to the cAMP-dependent PKA pathway Int. Immunopharmacol. 5 3 2005 609 618
115. M. Maes, B. Leonard, A. Fernandez, and M. Kubera (Neuro)inflammation and neuroprogression as new pathways and drug targets in depression: from antioxidants to kinase inhibitors Prog. Neuropsychopharmacol. Biol. Psychiatry 35 3 2011 659 663
116. M. Maes, H.Y. Meltzer, E. Bosmans, and R. Bergmans Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression J. Affect Disord. 34 4 1995 301 309
117. M. Maes, C. Song, A.H. Lin, and S. Bonaccorso Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion Neuropsychopharmacology 20 4 1999 370 379
118. M. Maes, R. Yirmyia, J. Noraberg, and S. Brene The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression Metab. Brain Dis. 24 1 2009 27 53
119. J.E. Malberg, and J.A. Blendy Antidepressant action: to the nucleus and beyond Trends Pharmacol. Sci. 26 12 2005 631 638
120. A. Mant, V.A. Rendle, W.D. Hall, and P.B. Mitchell Making new choices about antidepressants in Australia: the long view 1975-2002 Med. J. Aust. 181 Suppl. 7 2004 S21 S24
121. U. Martensson, and L. Nassberger Influence of antidepressants on mitogen stimulation of human lymphocytes Toxicol. In Vitro 7 3 1993 241 245
122. R.H. McAllister-Williams Do antidepressants work? A commentary on "initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration" by Kirsch et al Evid. Based Ment. Health 11 3 2008 66 68
123. E.M. McDonald, A.H. Mann, and H.C. Thomas Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers Lancet 2 8569 1987 1175 1178
124. J. Mendlewicz, P. Kriwin, P. Oswald, and D. Souery Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study Int. Clin. Psychopharmacol. 21 4 2006 227 231
125. H.J. Moller Antidepressants: controversies about their efficacy in depression, their effect on suicidality and their place in a complex psychiatric treatment approach World J. Biol. Psychiatry 10 3 2009 180 195
126. F.J. Monje, M. Cabatic, I. Divisch, and E.J. Kim Constant darkness induces IL-6-dependent depression-like behavior through the NF-kappaB signaling pathway J. Neurosci. 31 25 2011 9075 9083
127. S.A. Montgomery, D.S. Baldwin, and A. Riley Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction J. Affect Disord. 69 1-3 2002 119 140
128. P. Moore, H.P. Landolt, E. Seifritz, and C. Clark Clinical and physiological consequences of rapid tryptophan depletion Neuropsychopharmacology 23 6 2000 601 622
129. J.P. Mostert, F. Admiraal-Behloul, J.M. Hoogduin, and J. Luyendijk Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study J. Neurol. Neurosurg. Psychiatry 79 9 2008 1027 1031
130. N. Muller, and M.J. Schwarz The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression Mol. Psychiatry 12 11 2007 988 1000
131. N. Muller, M.J. Schwarz, S. Dehning, and A. Douhe The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine Mol. Psychiatry 11 7 2006 680 684
132. J.W. Murrough Ketamine as a novel antidepressant: from synapse to behavior Clin. Pharmacol. Ther. 91 2 2012 303 309
133. S. Nakajima, T. Suzuki, K. Watanabe, and H. Kashima Accelerating response to antidepressant treatment in depression: a review and clinical suggestions Prog. Neuropsychopharmacol. Biol. Psychiatry 34 2 2010 259 264
134. K. Narushima, S. Paradiso, D.J. Moser, and R. Jorge Effect of antidepressant therapy on executive function after stroke Br. J. Psychiatry 190 2007 260 265
135. J.C. Nelson The STAR*D study: a four-course meal that leaves us wanting more Am. J. Psychiatry 163 11 2006 1864 1866
136. NICE Depression: Management of Depression in Primary and Secondary Care Clinical Practice Guideline No 23 2004 National Institute for Clinical Excellence London
137. NICE The Treatment and Management of Depression in Adults Update 2009 National Institute for Clinical Excellence London
138. A.A. Nierenberg, A.H. Farabaugh, J.E. Alpert, and J. Gordon Timing of onset of antidepressant response with fluoxetine treatment Am. J. Psychiatry 157 9 2000 1423 1428
139. A. Niiranen, R. Laaksonen, M. Iivanainen, and K. Mattson Behavioral assessment of patients treated with alpha-interferon Acta Psychiatr. Scand. 78 5 1988 622 626
140. H.V. Nyback, J.R. Walters, G.K. Aghajanian, and R.H. Roth Tricyclic antidepressants: effects on the firing rate of brain noradrenergic neurons Eur. J. Pharmacol. 32 02 1975 302 312
141. J.C. O'Connor, M.A. Lawson, C. Andre, and E.M. Briley Induction of IDO by bacille Calmette-Guerin is responsible for development of murine depressive-like behavior J. Immunol. 182 5 2009 3202 3212
142. J.B. O'Sullivan, K.M. Ryan, N.M. Curtin, and A. Harkin Noradrenaline reuptake inhibitors limit neuroinflammation in rat cortex following a systemic inflammatory challenge: implications for depression and neurodegeneration Int. J. Neuropsychopharmacol. 12 5 2009 687 699
143. M. Olfson, and S.C. Marcus National patterns in antidepressant medication treatment Arch. Gen. Psychiatry 66 8 2009 848 856
144. M.J. Owens, W.N. Morgan, S.J. Plott, and C.B. Nemeroff Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites J. Pharmacol. Exp. Ther. 283 3 1997 1305 1322
145. A. Palucha, and A. Pilc The involvement of glutamate in the pathophysiology of depression Drug News Perspect. 18 4 2005 262 268
146. G.I. Papakostas, D. Charles, and M. Fava Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder World J. Biol. Psychiatry 11 2 Pt 2 2010 300 307
147. G. Parker The contribution of precipitants to depression onset, diagnostic sub-type, and treatment paradigm: a "mix and match" model Depress. Anxiety 27 9 2010 787 790
148. G. Parker Classifying clinical depression: an operational proposal Acta Psychiatr. Scand. 123 4 2011 314 316
149. G. Parker, M. Fink, E. Shorter, and M.A. Taylor Issues for DSM-5: whither melancholia? The case for its classification as a distinct mood disorder Am. J. Psychiatry 167 7 2010 745 747
150. J.A. Pasco, F.N. Jacka, L.J. Williams, and M.J. Henry Clinical implications of the cytokine hypothesis of depression: the association between use of statins and aspirin and the risk of major depression Psychother. Psychosom. 79 5 2010 323 325
151. N.D. Perkins Integrating cell-signalling pathways with NF-kappaB and IKK function Nat. Rev. Mol. Cell. Biol. 8 1 2007 49 62
152. P.A. Pirraglia, R.S. Stafford, and D.E. Singer Trends in prescribing of selective serotonin reuptake inhibitors and other newer antidepressant agents in adult primary care Prim. Care Companion J. Clin. Psychiatry 5 4 2003 153 157
153. Y. Pollak, E. Orion, I. Goshen, and H. Ovadia Experimental autoimmune encephalomyelitis-associated behavioral syndrome as a model of 'depression due to multiple sclerosis' Brain Behav. Immun. 16 5 2002 533 543
154. L. Probert, K. Akassoglou, M. Pasparakis, and G. Kontogeorgos Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha Proc. Natl. Acad. Sci. U. S. A. 92 24 1995 11294 11298
155. J.J. Radley, A.B. Rocher, A. Rodriguez, and D.B. Ehlenberger Repeated stress alters dendritic spine morphology in the rat medial prefrontal cortex J. Comp. Neurol. 507 1 2008 1141 1150
156. C.L. Raison, and A.H. Miller Is depression an inflammatory disorder? Curr. Psychiatry Rep. 13 6 2011 467 475
157. G. Rajkowska Cell pathology in mood disorders Semin. Clin. Neuropsychiatry 7 4 2002 281 292
158. A. Reichenberg, R. Yirmiya, A. Schuld, and T. Kraus Cytokine-associated emotional and cognitive disturbances in humans Arch. Gen. Psychiatry 58 5 2001 445 452
159. S. Reid, and C. Barbui Long term treatment of depression with selective serotonin reuptake inhibitors and newer antidepressants BMJ 340 2010 c1468
160. H. Renz, J.H. Gong, A. Schmidt, and M. Nain Release of tumor necrosis factor-alpha from macrophages. Enhancement and suppression are dose-dependently regulated by prostaglandin E2 and cyclic nucleotides J. Immunol. 141 7 1988 2388 2393
161. E. Richelson Pharmacology of antidepressants Mayo Clin. Proc. 76 5 2001 511 527
162. S.P. Roose, and A.H. Glassman Antidepressant choice in the patient with cardiac disease: lessons from the Cardiac Arrhythmia Suppression Trial (CAST) studies J. Clin. Psychiatry 55 Suppl. A 1994 83 87 discussion 88-89, 98-100
163. S.P. Roose, A.H. Glassman, E. Attia, and S. Woodring Cardiovascular effects of fluoxetine in depressed patients with heart disease Am. J. Psychiatry 155 5 1998 660 665
164. R.C. Rosen, R.M. Lane, and M. Menza Effects of SSRIs on sexual function: a critical review J. Clin. Psychopharmacol. 19 1 1999 67 85
165. H.G. Ruhe, N.S. Mason, and A.H. Schene Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies Mol. Psychiatry 12 4 2007 331 359
166. A.J. Rush Limitations in efficacy of antidepressant monotherapy J. Clin. Psychiatry 68 Suppl. 10 2007 8 10
167. P. Sacerdote, M. Bianchi, and A.E. Panerai Chlorimipramine and nortriptyline but not fluoxetine and fluvoxamine inhibit human polymorphonuclear cell chemotaxis in vitro Gen. Pharmacol. 25 3 1994 409 412
168. S. Sacre, M. Medghalchi, B. Gregory, and F. Brennan Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors Arthritis Rheum. 62 3 2010 683 693
169. C. Sangdee, and D.N. Franz Enhancement of central norepinephrine and 5-hydroxytryptamine transmission by tricyclic antidepressants. A comparison Psychopharmacology (Berl) 62 1 1979 9 16
170. J.J. Schildkraut The catecholamine hypothesis of affective disorders: a review of supporting evidence Am. J. Psychiatry 122 5 1965 509 522
171. I. Setnikar, M. Salvaterra, and O. Temelcou Antiphlogistic activity of iproniazid Br. J. Pharmacol. Chemother. 14 1959 484 487
172. R.P. Shank, J.L. Vaught, K.A. Pelley, and P.E. Setler McN-5652: a highly potent inhibitor of serotonin uptake J. Pharmacol. Exp. Ther. 247 3 1988 1032 1038
173. R.C. Shelton, J. Claiborne, M. Sidoryk-Wegrzynowicz, and R. Reddy Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression Mol. Psychiatry 16 7 2011 751 762
174. S.I. Shyn, and S.P. Hamilton The genetics of major depression: moving beyond the monoamine hypothesis Psychiatr. Clin. North. Am. 33 1 2010 125 140
175. R.S. Smith The macrophage theory of depression Med. Hypotheses 35 4 1991 298 306
176. F. Song, N. Freemantle, T.A. Sheldon, and A. House Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability BMJ 306 6879 1993 683 687
177. M. Spedding, and P. Gressens Neurotrophins and cytokines in neuronal plasticity Novartis Found. Symp. 289 2008 222 233 discussion 233-240
178. D.R. Spriggs, M.L. Sherman, H. Michie, and K.A. Arthur Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study J. Natl. Cancer Inst. 80 13 1988 1039 1044
179. L. Stafford, and M. Berk The use of statins after a cardiac intervention is associated with reduced risk of subsequent depression: proof of concept for the inflammatory and oxidative hypotheses of depression? J. Clin. Psychiatry 72 9 2011 1229 1235
180. S.M. Stahl Blue genes and the monoamine hypothesis of depression J. Clin. Psychiatry 61 2 2000 77 78
181. S.M. Stahl Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Apllications 2008 Cambridge University Press Cambridge
182. S.M. Stahl, and A. Felker Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants CNS Spectr. 13 10 2008 855 870
183. D.C. Steffens, K.R. Krishnan, and M.J. Helms Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis Depress. Anxiety 6 1 1997 10 18
184. J. Steiner, M. Walter, T. Gos, and G.J. Guillemin Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J. Neuroinflammation 8 2011 94
185. M. Stone, T. Laughren, M.L. Jones, and M. Levenson Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration BMJ 339 2009 b2880
186. D. Strumper, M.E. Durieux, M.W. Hollmann, and B. Troster Effects of antidepressants on function and viability of human neutrophils Anesthesiology 98 6 2003 1356 1362
187. T. Suzuki, H. Uchida, and S. Nakajima Depression severity and effect of antidepressant medications JAMA 303 16 2010 1597 1598 author reply 1599
188. A. Tadic, I. Helmreich, R. Mergl, and M. Hautzinger Early improvement is a predictor of treatment outcome in patients with mild major, minor or subsyndromal depression J. Affect Disord. 120 1-3 2010 86 93
189. Y.H. Tai, R.Y. Tsai, S.L. Lin, and C.C. Yeh Amitriptyline suppresses neuroinflammation-dependent interleukin-10-p38 mitogen-activated protein kinase-heme oxygenase-1 signaling pathway in chronic morphine-infused rats Anesthesiology 110 6 2009 1379 1389
190. M. Taler, I. Gil-Ad, I. Korob, and A. Weizman The immunomodulatory effect of the antidepressant sertraline in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis Neuroimmunomodulation 18 2 2011 117 122
191. M. Taler, I. Gil-Ad, L. Lomnitski, and I. Korov Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression Eur. Neuropsychopharmacol. 17 12 2007 774 780
192. S. Tanaka, M. Ide, T. Shibutani, and H. Ohtaki Lipopolysaccharide-induced microglial activation induces learning and memory deficits without neuronal cell death in rats J. Neurosci. Res. 83 4 2006 557 566
193. M.J. Taylor, N. Freemantle, J.R. Geddes, and Z. Bhagwagar Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis Arch. Gen. Psychiatry 63 11 2006 1217 1223
194. M.J. Taylor, S. Sen, and Z. Bhagwagar Antidepressant response and the serotonin transporter gene-linked polymorphic region Biol. Psychiatry 68 6 2010 536 543
195. M.E. Thase Effectiveness of antidepressants: comparative remission rates J. Clin. Psychiatry 64 Suppl. 2 2003 3 7
196. M.E. Thase Are SNRIs more effective than SSRIs? A review of the current state of the controversy Psychopharmacol. Bull. 41 2 2008 58 85
197. M.E. Thase, A.R. Entsuah, and R.L. Rudolph Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors Br. J. Psychiatry 178 2001 234 241
198. J.P. Ting, J.A. Duncan, and Y. Lei How the noninflammasome NLRs function in the innate immune system Science 327 5963 2010 286 290
199. M.H. Trivedi, A.J. Rush, S.R. Wisniewski, and A.A. Nierenberg Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice Am. J. Psychiatry 163 1 2006 28 40
200. R.J. Tynan, J. Weidenhofer, M. Hinwood, and M.J. Cairns A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia Brain Behav. Immun. 26 3 2012 469 479
201. S. Tyring, A. Gottlieb, K. Papp, and K. Gordon Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial Lancet 367 9504 2006 29 35
202. D. van Calker, I. Zobel, P. Dykierek, and C.M. Deimel Time course of response to antidepressants: predictive value of early improvement and effect of additional psychotherapy J. Affect Disord. 114 1-3 2009 243 253
203. M. Vaswani, F.K. Linda, and S. Ramesh Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review Prog. Neuropsychopharmacol. Biol. Psychiatry 27 1 2003 85 102
204. J. Vetulani, and F. Sulser Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain Nature 257 5526 1975 495 496
205. P. Vollmar, S. Nessler, S.R. Kalluri, and H.P. Hartung The antidepressant venlafaxine ameliorates murine experimental autoimmune encephalomyelitis by suppression of pro-inflammatory cytokines Int. J. Neuropsychopharmacol. 12 4 2009 525 536
206. K. Wager-Smith, and A. Markou Depression: a repair response to stress-induced neuronal microdamage that can grade into a chronic neuroinflammatory condition? Neurosci. Biobehav Rev. 35 3 2011 742 764
207. L.M. Wagner, J.P. Perentesis, J.M. Reid, and M.M. Ames Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study Pediatr. Blood Cancer 54 4 2010 538 545
208. F.R. Walker, N.A. Hodyl, K.M. Krivanek, and D.M. Hodgson Early life host-bacteria relations and development: long-term individual differences in neuroimmune function following neonatal endotoxin challenge Physiol. Behav. 87 1 2006 126 134
209. C.L. Wellman, A. Izquierdo, J.E. Garrett, and K.P. Martin Impaired stress-coping and fear extinction and abnormal corticolimbic morphology in serotonin transporter knock-out mice J. Neurosci. 27 3 2007 684 691
210. C.J. Whittington, T. Kendall, P. Fonagy, and D. Cottrell Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data Lancet 363 9418 2004 1341 1345
211. WHO WHO The Global Burden of Disease 2004 Update 2004 Switzerland
212. M.L. Wong, C. Dong, J. Maestre-Mesa, and J. Licinio Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response Mol. Psychiatry 13 8 2008 800 812
213. C.W. Wu, Y.C. Chen, L. Yu, and H.I. Chen Treadmill exercise counteracts the suppressive effects of peripheral lipopolysaccharide on hippocampal neurogenesis and learning and memory J. Neurochem. 103 6 2007 2471 2481
214. Z. Xia, J.W. Depierre, and L. Nassberger The tricyclic antidepressants clomipramine and citalopram induce apoptosis in cultured human lymphocytes J. Pharm. Pharmacol. 48 1 1996 115 116
215. Z. Xia, J.W. DePierre, and L. Nassberger Tricyclic antidepressants inhibit IL-6, IL-1 beta and TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T cells Immunopharmacology 34 1 1996 27 37
216. M. Yamada, and T. Higuchi Functional genomics and depression research. Beyond the monoamine hypothesis Eur. Neuropsychopharmacol. 12 3 2002 235 244
217. R. Yirmiya Endotoxin produces a depressive-like episode in rats Brain Res. 711 1-2 1996 163 174
218. M. Yoshikawa, A. Suzumura, T. Tamaru, and T. Takayanagi Effects of phosphodiesterase inhibitors on cytokine production by microglia Mult. Scler. 5 2 1999 126 133
219. J. Zhu, X. Wei, J. Liu, and Y. Hu Interaction of glia activation and neurotransmission in hippocampus of neuropathic rats treated with mirtazapine Exp. Clin. Psychopharmacol. 17 3 2009 198 203
220. J. Zou, and F. Crews CREB and NF-kappaB transcription factors regulate sensitivity to excitotoxic and oxidative stress induced neuronal cell death Cell. Mol. Neurobiol. 26 4-6 2006 385 405